Please use this identifier to cite or link to this item:
Title: Current therapies and novel approaches for biliary diseases.
Austin Authors: Rajapaksha, Indu G;Angus, Peter W ;Herath, Chandana B
Affiliation: Department of Gastroenterology and Hepatology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
Issue Date: 5-Jan-2019
Publication information: World journal of gastrointestinal pathophysiology 2019; 10(1): 1-10
Abstract: Chronic liver diseases that inevitably lead to hepatic fibrosis, cirrhosis and/or hepatocellular carcinoma have become a major cause of illness and death worldwide. Among them, cholangiopathies or cholestatic liver diseases comprise a large group of conditions in which injury is primarily focused on the biliary system. These include congenital diseases (such as biliary atresia and cystic fibrosis), acquired diseases (such as primary sclerosing cholangitis and primary biliary cirrhosis), and those that arise from secondary damage to the biliary tree from obstruction, cholangitis or ischaemia. These conditions are associated with a specific pattern of chronic liver injury centered on damaged bile ducts that drive the development of peribiliary fibrosis and, ultimately, biliary cirrhosis and liver failure. For most, there is no established medical therapy and, hence, these diseases remain one of the most important indications for liver transplantation. As a result, there is a major need to develop new therapies that can prevent the development of chronic biliary injury and fibrosis. This mini-review briefly discusses the pathophysiology of liver fibrosis and its progression to cirrhosis. We make a special emphasis on biliary fibrosis and current therapeutic options, such as angiotensin converting enzyme-2 (known as ACE2) over-expression in the diseased liver as a novel potential therapy to treat this condition.
DOI: 10.4291/wjgp.v10.i1.1
PubMed URL: 30622832
ISSN: 2150-5330
Type: Journal Article
Subjects: Angiotensin converting enzyme-2
Biliary fibrosis
Chronic liver disease
Current therapies for biliary fibrosis
Gene therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 28, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.